NCT00076635View on ClinicalTrials.gov

An Open-Label Study of the Safety of Interferon Gamma-1b in Patients With IPF

PHASE3TerminatedINTERVENTIONAL
Enrollment

91

Participants

Timeline

Start Date

November 30, 2003

Study Completion Date

April 30, 2007

Conditions
Idiopathic Pulmonary FibrosisPulmonary FibrosisLung Disease
Interventions
DRUG

Interferon gamma-1b

200 mcg, SQ, 3x per week

Trial Locations (1)

94005

Intermune Inc, Brisbane

Sponsors

Lead Sponsor

InterMune
All Listed Sponsors
lead

InterMune

INDUSTRY

NCT00076635 - An Open-Label Study of the Safety of Interferon Gamma-1b in Patients With IPF | Biotech Hunter | Biotech Hunter